Wegovy Cost: Monthly Price, Insurance Coverage, and $0 Copay Options

Wegovy’s list price hit $1,349/month in 2024. But Novo Nordisk’s savings program can bring it to $0/month for commercially insured patients who qualify — zero dollars. That’s not a typo, and understanding why explains exactly how drug pricing in the US actually works.

The Sticker Price vs. What People Actually Pay

Wegovy (semaglutide 2.4mg injection, weekly) is FDA-approved specifically for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related condition. That obesity indication — not diabetes — is what defines its formulary status and savings card eligibility.

The $0 Copay Program: Who Qualifies

Novo Nordisk’s Wegovy savings program — currently offering $0/month copay — applies to commercially insured patients whose insurance covers Wegovy. The key phrase: “whose insurance covers Wegovy.”

This is the distinction that trips people up. The savings card offsets what you’d otherwise owe in copays or coinsurance after your insurance pays its share. If your insurance doesn’t cover Wegovy at all, the savings card gets you a flat rate — typically capped at a manufacturer-set discount — not zero dollars.

Eligibility requirements for the $0 copay offer (as of 2025–2026):

• Commercial insurance that covers Wegovy on formulary
• No government-funded coverage (Medicare, Medicaid, TRICARE, Veterans Affairs)
• US residency with a valid prescription
• Enrollment through the Novo Nordisk savings card portal

Novo Nordisk reports on its corporate materials that roughly 50% of commercially insured patients who are prescribed Wegovy end up paying $25/month or less after savings programs. The $0 tier is real, but it requires your plan to cover the drug.

What Drives Wegovy Insurance Coverage

Coverage has expanded substantially since Wegovy’s FDA approval in 2021. A 2024 JAMA Health Forum study found that 55% of large-employer plans had added some form of GLP-1 coverage for obesity by 2024, up from 27% in 2021.

What determines your coverage:

• Employer plan design. Large self-insured employers can add or exclude drug classes as they choose. Many have added obesity drugs after the SELECT cardiovascular outcomes trial.
• PBM formulary tier. Express Scripts, CVS Caremark, and OptumRx tier medications differently. Wegovy on a preferred Tier 2 might mean a $50 copay; on Tier 4 non-preferred it could be $400+.
• PA requirements. Virtually every commercial plan requires prior authorization. Common criteria: BMI documentation, comorbidity diagnosis (hypertension, sleep apnea, type 2 diabetes, dyslipidemia), and often a note about prior behavioral weight management attempts.

Medicare Part D: The Coverage Gap Problem

Medicare Part D does not use manufacturer savings cards — federal law prohibits them. For Medicare beneficiaries, Wegovy costs depend entirely on your specific Part D plan’s formulary.

As of 2026, some Part D plans have added Wegovy to formulary, especially following the SELECT trial results showing 20% cardiovascular event reduction. Your annual out-of-pocket max under Medicare’s redesigned Part D benefit is $2,000 — so in a worst-case scenario, your maximum exposure is capped there.

Medicare Advantage plans have more flexibility and some have added obesity drug coverage. If you’re on Medicare and want Wegovy, comparing Medicare Advantage plans during open enrollment specifically for GLP-1 coverage is worth doing.

The Duration Problem: Cost Over Time

Wegovy isn’t a short course of treatment. Clinical evidence is clear that weight regain begins promptly after stopping — the STEP 4 extension study showed participants regained 6.9% of their body weight within 52 weeks of discontinuation after achieving 10.6% weight loss on drug.

At list price, 5 years of Wegovy without insurance costs $78,000–$96,000. Even with good insurance at $25/month, it’s $1,500 over 5 years — affordable, but the drug needs to be continually available on your formulary and your employer can’t change coverage.

That permanence is a meaningful factor when comparing Wegovy against one-time surgical options like gastric sleeve or gastric bypass. The surgical premium gets smaller every year you’d otherwise need to fund the medication.

Alternatives If You Can’t Access Wegovy

Compounded semaglutide. Telehealth platforms like Hims, Ro, and others prescribe compounded semaglutide (not FDA-approved Wegovy) for $200–$500/month. During FDA shortage status, this is legal, but quality consistency is less certain than with branded products. The FDA shortage designation for semaglutide injectable products has fluctuated — check current status before starting.

Ozempic off-label. Some prescribers use Ozempic (lower-dose semaglutide, FDA-approved for diabetes) off-label for weight management. Costs can be lower with diabetes-indication coverage. See our Ozempic cost guide for the detailed breakdown.

Other GLP-1s. Mounjaro and Zepbound (tirzepatide) have shown higher weight loss in trials and have their own cost structures — worth comparing if Wegovy coverage is denied.

Bottom Line

Wegovy’s list price is $1,349–$1,600/month. If your commercial insurance covers it and you’re not on Medicare, the savings card can bring that to $0–$25/month — transforming affordability. The challenge is getting insurance coverage in the first place, which requires prior authorization with BMI and comorbidity documentation. Plan for 5–14 days of PA processing, have your doctor ready to appeal if denied, and check PBM tier placement before filling.